SRPT ALERT: Levi & Korsinsky Investigates Sarepta Therapeutics, Inc. on Behalf of Shareholders Who Lost Money

NEW YORK, NY / ACCESS Newswire / June 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ:SRPT) concerning possible violations of federal securities laws.

On June 16, 2025, Sarepta reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne muscular dystrophy patient. Accordingly, management announced it suspended commercial shipments of Elevidys in the non-ambulatory setting and paused dosing in its confirmatory ENVISION trial. Analysts note the "broader concerns around safety and regulatory scrutiny could weigh on near-term performance."

Following this news, SRPT 's stock price fell by $15.24 per share, or approximately 42% to close at $20.94.
To obtain additional information, go to:

https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=154507&wire=1&utm_campaign=41

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.

WHY LEVI & KORSINSKY:Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services ' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/

SOURCE:Levi & Korsinsky, LLP

View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire. All Rights Reserved.